


Technical Information about 6-Cl-cPuMP

Cyclic nucleotide with reactive chlorine in 6-position

Update: August 07, 2018 HU



Abbreviation: 6-Cl-cPuMP

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
C ₁₀ H ₉ ClN ₄ O ₆ P·Na	[94200-58-5]	370.6	λ _{max} 263 nm / ε 8900 / pH7	C 002

Name: 6- Chloropurine riboside- 3', 5'- cyclic monophosphate

Description: 6-Cl-cPuMP is an analogue of the natural signal molecule cyclic AMP in which the amino group in position 6 of the heterocyclic nucleobase is replaced by a chlorine atom.

Properties: Analogue of cyclic AMP showing better membrane permeability and higher stability against phosphodiesterases. 6-Cl-cPuMP is suitable for nucleophilic substitutions at the 6-position with affinity spacers or various labels.

Specification: Crystallized or lyophilized sodium salt. Other salt forms of 6-Cl-cPuMP are available upon request. Please keep in mind that equal amounts of the compound may look different in volume due to sensitivity of the lyophilized form to humidity. The compound can even contract to small volume droplets. Normally the product is located in the conical bottom of the tube. Micro molar quantities are determined by UV at λ_{max}.

Purity: Typical analysis is better than 98% (HPLC / UV / 263 nm). The product is not sterile and has not been tested for endotoxins.

Solubility: 6-Cl-cPuMP is readily soluble in water or buffers. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing. When opening the tube please make sure that no substance is lost within the cap.

Stability and Storage: 6-Cl-cPuMP has sufficient stability at room temperature and does not need special care during handling or shipment. Nevertheless, we recommend that the compound should be stored in the freezer, for longer storage periods preferably in freeze-dried form.

Toxicity and Safety: Since cyclic AMP has multiple tasks in every organism, it is very likely that lipophilic cAMP analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with, no health hazards have been reported. Nevertheless please keep in mind, that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.

Our products are designed, developed and sold for research purposes only! They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.

Not for drug, household or related uses!

Selected References for 6-Cl-cPuMP :

- Jäger, R.; Russwurm, C.; Schwede, F.; Genieser, H.-G.; Koesling, D.; Russwurm, M., *J. Biol. Chem.*, **287**, 1210 - 1219 (2012): „Activation of PDE10 and PDE11 Phosphodiesterases“
- Hofbauer, K.; Schultz, A.; Schultz, J.E., *J. Biol. Chem.*, **283**, 25164 - 25170 (2008): „Functional Chimeras of the Phosphodiesterase 5 and 10 Tandem GAF Domains“
- Scott, S.-P.; Shea, P.W.; Dryer, S.E., *Biochemistry*, **46**, 9417 - 9431 (2007): "Mapping Ligand Interactions with the Hyperpolarization Activated Cyclic Nucleotide Modulated (HCN) Ion Channel Binding Domain Using a Soluble Construct"
- Feldwisch, O.; Lammertz, M.; Hartmann, E.; Feldwisch, J.; Palme, K.; Jastorff, B.; Jaenicke, L., *Eur. J. Biochem.*, **228**, 480 - 489 (1995): "Purification and Characterization of a cAMP-binding Protein of *Volvox carteri f.nagariensis* lyengar"
- Ruchaud, S.; Zorn, M.; Davilar-Villar, E.; Genieser, H.-G.; Hoffmann, C.; Gjertsen, B.T.; Døskeland, S.O.; Jastorff, B.; Lanotte, M., *Cell. Pharmacol.*, **2**, 127 - 140 (1995): "Evidence for Several Pathways of Biological Response to Hydrolysable cAMP-analogues Using a Model System of Apoptosis in IPC-81 Leukaemia Cells"
- Peters, D.J.M.; Bominaar, A.A.; Snaar-Jagalska, B.E.; Brandt, R.; Van Haastert, P.J.M.; Ceccarelli, A.; Williams, J.G.; Schaap, P., *Proc. Natl. Acad. Sci. USA*, **88**, 9219 - 9223 (1991): "Selective Induction of Gene Expression and Second-Messenger Accumulation in Dictyostelium Discoideum by the Partial Chemotactic Antagonist 8-p-chlorophenylthioadenosine 3',5'-cyclic Monophosphate"
- Øgreid, D.; Ekanger, R.; Suva, R.H.; Miller, J.P.; Døskeland, S.O., *Eur.J.Biochem.*, **181**, 19 - 31 (1989): "Comparison of the Two Classes of Binding Sites (A and B) of Type I and Type II Cyclic-AMP-dependent Protein Kinases Using Cyclic Nucleotide Analogs"
- Ebright, R.H.; Le Grice, S.F.J.; Miller, J.P.; Krakow, J.S., *J. Mol. Biol.*, **182**, 91 - 107 (1985): "Analogues of Cyclic AMP that Elicit the Biochemically Defined Conformational Change in Catabolite Gene Activator Protein (CAP) but do not Stimulate Binding to DNA"
- Miller, J.P.; Boswell, K.H.; Meyer, R.B.; Christensen, L.F.; Robins, R.K., *J. Med. Chem.*, **23**, 242 - 251 (1980): "Synthesis and Enzymatic and Inotropic Activity of Some New 8-Substituted and 6,8-Disubstituted Derivatives of Adenosine Cyclic 3',5' - Monophosphate"
- Michal, G.; Mühlegger, K.; Nelboeck, M.; Thiessen, C.; Weimann, G., *Pharmacol. Res. Commun.*, **6**, 203 - 252 (1974): "Cyclophosphates VI. Cyclophosphates as Substrates and Effectors of Phosphodiesterase"